15 -5 (91) 2026 - Abdullaev Sh.O., Ahmed Taufik Ali Ibrahim - DIABETIC RETINOPATHY: MODERN MANAGEMENT ALGORITHMS AND THERAPEUTIC STRATEGIES

DIABETIC RETINOPATHY: MODERN MANAGEMENT ALGORITHMS AND THERAPEUTIC STRATEGIES

Abdullaev Sh.O. - Andijan State Medical Institute, Uzbekistan

Ahmed Taufik Ali Ibrahim - Zagazik University, Arab Republic of Egypt

Abdullaeva S.M. - Andijan State Medical Institute, Uzbekistan

Resume

Diabetic retinopathy (DR) is one of the leading causes of vision loss and blindness among working-age individuals. According to international studies, the prevalence of DR reaches 30–35% among patients with diabetes, with vision-threatening forms occurring in approximately 10%. Current guidelines from the American Academy of Ophthalmology and data from randomized clinical trials confirm the high efficacy of anti-VEGF therapy in the treatment of diabetic macular edema (DME) and proliferative diabetic retinopathy. The aim of this study is to systematize current approaches to managing patients with DR and evaluate the effectiveness of combination therapy using sub-Tenon's sodium hyaluronate.

Keywords: diabetic retinopathy, DME, anti-VEGF, OCT, combination therapy

First page

90

Last page

94

For citation:Abdullaev Sh.O., Ahmed Taufik Ali Ibrahim, Abdullaeva S.M. - DIABETIC RETINOPATHY: MODERN MANAGEMENT ALGORITHMS AND THERAPEUTIC STRATEGIES//New Day in Medicine 5(91)2026 90-94 https://newdayworldmedicine.com/en/new_day_medicine/5-91-2026

List of References

  1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Arch Ophthalmol. 1985;103(12):1796-1806.
  2. Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-1203. doi:10.1056/NEJMoa1414264.
  3. Brown DM, Nguyen QD, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022. doi:10.1016/j.ophtha.2013.02.034.
  4. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-2385. doi:10.1016/j.ophtha.2016.07.032.
  5. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625. doi:10.1016/j.ophtha.2011.01.031.
  6. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco (CA): American Academy of Ophthalmology; 2023.
  7. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487. doi:10.1056/NEJM199412013312203.
  8. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227-1239. doi:10.1056/NEJMra1005073.
  9. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-136. doi:10.1016/S0140-6736(09)62124-3.
  10. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351-1359. doi:10.1016/j.ophtha.2016.02.022.

    file

    download